期刊
BLOOD REVIEWS
卷 34, 期 -, 页码 34-44出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2018.11.001
关键词
Allogeneic hematopoietic cell transplantation; Conditioning; Graft-versus-host disease; Relapse
类别
资金
- Leon Levine Foundation
- Kerry
Allogeneic hematopoietic cell transplantation (HCT) provides the best chance for cure for many patients with malignant and nonmalignant hematologic disorders. Recent advances in selecting candidates and determining risk, procedure safety, utilization in older patients, use of alternative donors, and new or novel application of anti-cancer, immunosuppressive and antimicrobial agents have improved outcomes and expanded the role of HCT in hematologic disorders. Relapse remains the predominant cause of failure but enlightened use of new targeted and immunotherapeutic agents in combination with HCT promises to reduce relapse and further improve HCT outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据